IMCR News and Press, Immunocore Holdings plc From 06/25/22

P RESS RELEASE Immunocore announces the presentation of initial data from the P hase 1 ImmTAV ® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC- I109V , T cell recep...

Immunocore (NASDAQ:IMCR) said on Friday that Ocumel Canada and Save Your Skin Foundation applauded Canada's approval of Kimmtrak to treat a type of rare cancer called uveal melanoma. Uveal melanoma is a type of cancer that begins in the cells that make the dark-colored pigment, called melanin...

The following slide deck was published by Immunocore Holdings plc in conjunction with this event. For further details see: Immunocore Holdings (IMCR) Investor Presentation - Slideshow

Immunocore Appoints Sidd h art h Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commer...

The U.K. Medicines and Healthcare products Regulatory Agency, Australian Therapeutic Goods Administration and Health Canada granted marketing authorization to Immunocore's (NASDAQ:IMCR) Kimmtrak  to treat HLA-A 02:01-positive adult patients with unresectable or metastatic uveal mela...

The UK Medicine s and Healthcare products Regulatory Agency ( MHRA ) , Australian Therapeutic Goods Administration (TGA) and Health Canada a pprove KIMMTRAK® ( tebentafusp ) for the treatment of unresectable or metastatic uveal ...

P RESS RELEASE Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Tebentafusp and anti-PDL1 show 1 ye...

Commercial-stage biotech Immunocore Holdings (NASDAQ:IMCR) announced Friday that Sanofi (SNY) (OTCPK:SNYNF) has entered into a clinical trial collaboration and supply agreement with the company to target certain patients with advanced skin cancers. Per the terms, Sanofi (SNY) will assess its ...

Immunocore announce s c linical t rial c ollaboration with Sanofi to evaluate Sanofi’s product candidate SAR 444 245 , non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous me...

P RESS RELEASE Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Updated overall survival (OS) data from Ph ase 1b metastatic cutaneous melanoma trial O ral pr...